Study Finds Pradaxa Bleeding Risks Outweigh Possible Benefits of Anticoagulant Drug

May 24, 2014
by The Atkins & Markoff Team

Study Finds Pradaxa Bleeding Risks Outweigh Possible Benefits of Anticoagulant Drug

According to new research, the risk of bleeding complications associated with Pradaxa and other new-generation blood thinners may outweigh all of their possible benefits. In a report published online recently by the Archives of Internal Medicine, European researchers performed a seven-study meta analysis of severe bleeding side effects that occurred after the use of blood thinners like Pradaxa. Study authors found that medications known as Xa inhibitors and direct thrombin inhibitors have a high enough rate of bleeding events that the complications may diminish the benefits provided by the medication. If you took the blood thinner Pradaxa and have since suffered from a serious bleeding side effect, contact our qualified Pradaxa attorneys at AMA Law for legal help. Our drug injury lawyers have extensive experience protecting the rights of consumers injured by faulty medications, and can help you pursue compensation for your drug-related injuries.


The researchers involved in the study reviewed the databases of research involving patients who were administered blood thinners after suffering acute coronary syndrome (ACS), and placebo-controlled clinical trials that included more than 30,000 patients. According to the study, there was a three-times increased risk of bleeding events among patients taking a new-generation blood thinner, but only moderate reductions in the risk of stent thrombosis or additional heart problems, and no significant effect on the survival of the patient. “For the net clinical benefit, treatment with new-generation oral anticoagulant agents provided no advantage over placebo,” the authors reported. “The use of anti-Xa or direct thrombin inhibitors is associated with a dramatic increase in major bleeding events, which might offset all ischemic benefits in patients receiving antiplatelet therapy after an ACS.”


The most popular drugs in the class of blood thinners known as direct thrombin inhibitors is Pradaxa, a drug introduced in October 2010 and manufactured by Boehringer Ingelheim. Despite Pradaxa’s short time on the market so far, serious concerns have been raised about the safety of the medication since its introduction, particularly related to the risk of death or catastrophic injury. In light of this potentially life-threatening side effect risk, a growing number of Pradaxa lawsuits have been filed against Boehringer Ingelheim, on behalf of patients who have been seriously injured or who lost loved ones due to the medication’s side effects. If you have suffered a major complication that you believe to be linked to the blood thinner Pradaxa, contact our skilled Pradaxa attorneys at AMA Law to discuss your legal options. You may have grounds to file a Pradaxa lawsuit against the drug maker, and our defective drug lawyers can help you explore your compensation options and seek fair and timely reimbursement for your injuries.